Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5955539 | 0.92 | ADAM17 (0.53) | ADAM17TNF | |
| SCHEMBL13201450 | 0.84 | ADAM17 (0.43) | ADAM17TNF | |
| SCHEMBL13218930 | 0.82 | ADAM17 (0.41) | ADAM17 | |
| SCHEMBL13201495 | 0.81 | DRD2 (0.49) | ADAM17TNF | |
| SCHEMBL10113050 | 0.78 | ADAM17 (0.49) | ADAM17TNF | |
| SCHEMBL10200126 | 0.77 | KMT2A (0.42) | ADAM17 | |
| SCHEMBL13201490 | 0.74 | PRMT5 (0.48) | — | |
| SCHEMBL10200992 | 0.73 | ADAM17 (0.60) | ADAM17TNF | |
| SCHEMBL8235144 | 0.71 | ADAM17 (0.58) | ADAM17TNF | |
| SCHEMBL12150406 | 0.71 | ADAM17 (0.65) | ADAM17TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541572-B2 | Compounds for the treatment of inflammatory disorders | MERCK SHARP & DOHME CORP. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | MERCK SHARP & DOHME CORP. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | ADAM17 7/4885TNF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.